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Abstract Tumor necrosis factor-alpha (TNF-α) contributes
in inflammation and has been implicated in the development
of colorectal cancer (CRC). Single nucleotide polymorphisms
(SNPs) in TNF-α promoter could affect the risk of CRC by
regulating TNF-α production. This is the first study to inves-
tigate TNF-α SNPs in a Middle Eastern population. In this
study, we examined three SNPs in TNF-α for association with
CRC. One hundred CRC patients and 100 controls were ge-
notyped for TNF-α -308, -238, and -857 using TaqMan allelic
discrimination assay. The TNF-α -238 (G/A) genotype was
significantly associated with high risk of CRC (p=
0.003552). The distribution of three genotypes of -238 G/A
was significantly different between the controls and CRC pa-
tients even after Bonferroni’s correction. The AA genotype of
-238 G/A SNP was observed at considerably higher propor-
tion (13%) in CRCs compared to controls (1%). Additionally,
similar to genotypes, the allelic frequencies of -238 G/Awere
significantly different between the CRC cases and controls
(odds ratios (OR)=7.647, χ2=18.50, p=0.00002). The geno-
type frequencies of -308 and -857 were not notably different
between the cases and controls. TNF-α -238A may be useful
as a screening marker to identify individuals prior to their
acquiring CRC in the Saudi population although, further val-
idations in larger cohorts are needed.
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Introduction
Colorectal cancer (CRC) is one of the most common cancers
worldwide. It is the third most common cancer in males and
the second in females. Incidence rates of CRC are rapidly
increasing in several areas in the world, probably related to a
combination of genetic factors as well as lifestyle changes
including diet, obesity, and smoking [1–3]. In the Kingdom
of Saudi Arabia, it ranks first in incidence among Saudi males
and third among Saudi females according to the Saudi Cancer
Registry data [4]. Reports from Saudi Arabia suggest that
CRC is a more aggressive disease in that population [5, 6].
Inflammation is one of the key factors involved in carcino-
genesis, and people with inflammatory bowel disease are at
higher risk of CRC [7]. Therefore, polymorphisms of
inflammation-related genes have been regarded as potential
sources of cancer risk biomarkers [8]. CRC arises from the
accumulation of mutations in oncogenes and tumor suppressor
genes during tumorigenesis [9]. Biological and epidemiological
studies indicated a clear association between chronic inflamma-
tion and colorectal cancer [10, 11]. In the recent years, cyto-
kines have received much attention due to their possible role in
tumorigenesis [12, 13]. Cytokines are important inflammatory
mediators that may act in a regulatory network to directly or
indirectly activate downstream signaling pathways key to the
development of malignancies [11, 14]. Human predisposition
to cancer could be influenced by single nucleotide
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polymorphisms (SNPs) located in genes encoding cytokines
and their receptors, especially in promoter regions [15].
Tumor necrosis factor-alpha (TNF-α) is an important pro-
inflammatory cytokine involved in cell growth, differentiation,
and apoptosis [16, 17]. It has also been reported to play a critical
role in the carcinogenesis [18]. The TNF-α gene is located on
chromosome 6p21.3. Cytokine production is controlled at the
transcriptional level, and many promoter polymorphisms have
been described [19]. Previous studies indicated that TNF-α-
related cellular functions were influenced by polymorphism in
the promoter region of the TNF-α gene [20–22]. Recently,
TNF-α was suggested to be one of the immunomodulatory
genes in the progression of sporadic CRC [23].
The aim of our study was to examine the allelic frequencies of
three promoter SNPs (-857 C/T, -308 G/A and -238 G/A) in
Saudi patients with CRC versus healthy controls, in order to
identify any association of these SNPs with susceptibility to
CRC. These SNPs were selected as they were the common
TNF-αSNP sites thatwere examined in other populations besides
being included in the SNP500Cancer project that aims to identify
and characterize genetic variants in genes important in cancer.
Material and methods
Study population
A total of 200 blood samples were obtained from King Khalid
University Hospital. These encompassed 100 patients with
sporadic colorectal cancer and 100 healthy controls with no
history of cancer. Colorectal cancer patients included patients
of all ages (median age=57 years) and all stages of the disease.
Patient blood samples were collected preoperatively. None of
the patients underwent preoperative irradiation or chemother-
apy. Diagnosis of CRC were established by standard diagnos-
tic procedures and confirmed histopathologically. Patients and
controls were from Saudi Arabian ethnicity. All controls were
gender- and age-matched and recruited from physical exami-
nations after diagnostic exclusion of cancer. The study com-
plied with the requirements, and has been approved by the
Ethics Committee of the King Saud University. Patient con-
sent was obtained for this study.
DNA extraction
Approximately 3 ml of blood samples were collected in
vacutainers containing ethylenediaminetetraacetic acid
(EDTA) from all subjects enrolled in the study. Genomic
DNA was extracted from peripheral blood using the
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA,
USA) and stored at −80 °C until the time of study. After
extraction and purification, the DNAwas quantitated spectro-
photometrically on NanoDrop 8000 (Thermo Scientific,
USA), and its purity examined using standard A260/A280
and A260/A230 ratios.
SNP selection and genotyping
A total of three important TNF-α SNPs were selected from the
SNP500 Cancer project and previous literature [24–26]. SNPs
were genotyped using TaqMan allelic discrimination assay as
previously described [27]. TaqMan TNF-α SNP Genotyping
Assays having catalogue number 4351379 and assay numbers
C_11918223_10 (rs1799724), C_7514879_10 (rs1800629),
and C_2215707_10 (rs361525) were acquired from Applied
Biosystems. These assays were supplied at 40X concentra-
tion. For each PCR, a 5-ng DNA sample was used with
12.5 μL of 2X Universal Master Mix and 1X assay mix in a
total of 25 μL reaction volume (Applied Biosystems, Foster
City, CA, USA). PCR conditions are as follows: pre-read
stage 60 °C for 30 s, hold stage 95 °C for 10 min, PCR stage
95 °C for 15 s and 60 °C for 1 min for 40 cycles, and post-read
stage 60 °C for 30 s. All genotypes were determined by end-
point reading on ViiA™ 7 Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). For quality control, 5 %
of the samples were randomly selected and subjected to repeat
analysis as measure for verification of genotyping procedures.
The results were reproducible without any discrepancies.
Statistical analysis
Comparisons of genotype and allelic frequencies in the CRC
group and healthy individuals were calculated according to
Pearson’s goodness-of-fit chi-square. Deviation from Hardy-
Weinberg equilibrium, χ2 values, odds ratios (OR), 95 % con-
fidence intervals (CI), and p values were calculated using the
web-based programs (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl,
http://www.socscistatistics.com). A p value of <0.05 was
considered as significant. Additionally, for multiple
comparisons of the three SNPs in the TNF-α gene that were
examined, Bonferroni’s correction was applied with an α=0.
0167 considered as significant.
Results
Genotype and allele association with CRC risk
To determine the risk of predisposition to colorectal cancer
with the genetic variants in the TNF-α gene, three different
loci comprising SNPs rs1800629, rs361525, and rs1799724
were examined in Saudi Arabian patients. All the three SNPs
are within 2 kb upstream of the 5′ region of the gene and hence
likely to be in the promoter. The study population comprised
100 colorectal cancer cases and the same number of age- and
gender-matched normal healthy individuals. The
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clinicopathological characteristics of CRC patients are pre-
sented in Table 1. The distribution of genotype and allele
frequencies of the analyzed SNPs along with odds ratio and
significance are shown in Table 2. The homozygous ancestral
allele was used as a reference to determine the risk of acquir-
ing CRCs associated with the other two genotypes. Of the
three SNPs in the TNF-α gene that were analyzed, statistically
significant association with CRC risk was observed only for
rs361525. The distribution of the three genotypes of rs361525
as GG, GA, and AA was significantly different between the
controls and CRC patients (χ2=11.28, df=2, p=0.003552).
The genotype frequencies for GG, GA, and AA in CRCs were
0.86, 0.01, and 0.13, whereas in healthy controls, it was found
to be 0.97, 0.02, and 0.01, respectively (Table 2). Thus, the
AA genotype was observed at significantly higher proportion
(13 %) in CRC cases compared to the control group (1 %). It
was found that the homozygous AA genotype of the TNF-α
SNP rs361525 posed approximately 14-fold higher risk for
developing CRC compared to individuals with the GG
genotype (OR=14.663, χ2=10.94, p=0.00094). It was also
noted that similar to genotypes, the distribution of allelic fre-
quencies of rs361525 was significantly different between the
CRC cases and controls (OR=7.647, χ2=18.50, p=0.00002).
The AA genotype as well as A allele of rs361525 was highly
significant even after Bonferroni’s correction for multiple
testing.
The distribution of genotype frequencies of rs1800629 was
not statistically significant between the CRC cases and con-
trols (χ2=2.79, df=2, p=0.247381). Although the AA geno-
type of rs1800629 was found in CRC cases at a lower fre-
quency (0.10) compared to controls (0.18) and conferred
about twofold decreased risk against CRCs, this association
was not statistically significant (OR=0.489, χ2=2.79, p=
0.09464) (Table 2). In case of rs1799724 polymorphism, the
distribution of genotype and allele frequencies between the
CRCs and healthy normal subjects were exactly similar
(Table 2). Only the CC and CT genotypes were observed
while the TT homozygotes were absent in both the cases
and control populations.
Association of TNF-α SNPs with CRC risk based on age
at disease diagnosis and gender
To investigate whether TNF-α SNPs rs1800629, rs361525,
and rs1799724 are associated with the age at CRC diagnosis,
patients were stratified based on the median age at the time of
disease diagnosis as ≤57 (n=50) and >57(n=50)years and the
genotype and allele frequencies were compared to the age-
matched controls. The distribution of genotype and allele fre-
quencies along with the statistical analysis of the three TNF-α
SNPs in CRC cases and normal control population in the two
age groups are shown in Table 3. Similar to the findings in the
overall study population, individuals with the AA homozy-
gosity compared to the GG homozygosity in rs361525 were
at significantly higher risk of developing CRCs. Additionally,
examination of the allelic frequencies of rs361525 suggested
that the minor allele A confers significantly higher risk of
developing CRCs. However, the genotype as well as allele
associations were not affected by the age at disease diagnosis
as they were observed in both age groups (Table 3). The ge-
notypes of rs1800629 and rs1799724 did not show any pre-
disposition to CRCs in younger as well as older age group
patients. Nonetheless, it was noted that the minor allele A of
rs1800629 exerts about twofold protective effect in patients
>57 years of age (OR=0.508, χ2=4.34, p=0.03726).
The prevalence of genotype and allele frequencies of the
three TNF-α SNPs that were examined in CRC cases and
normal control population according to the gender are present-
ed in Table 4. In both the male as well as female populations,
individuals with the AA genotype of rs361525 has significant-
ly higher risk of developing CRCs compared with those hav-
ing GG homozygosity (male—OR=10.333, χ2=6.95, p=
Table 1 Clinicopathological characteristics of colorectal cancer
patients
Variable Number of patients Percent


















Clinical staging (UICC 2010) and metastasis
Stage I 11 11
Stage II 58 58
Stage III 17 17
Metastasis 14 14
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0.00837; female—OR=9.831, χ2=4.12, p=0.04235).
Furthermore, based on the allelic model, the minor A allele
of rs361525 exhibited significant association with CRCs albe-
it not showing gender specificity (Table 4). The TNF-α poly-
morphisms rs1800629 and rs1799724 did not show any asso-
ciation with the risk of developing CRCs in males as well as in
females as was observed in the overall study population.
Discussion
Inflammation plays an important role in the pathogenesis of
CRC. TNF-α is a critical component in the inflammatory
pathway whose level is known to be upregulated in CRC
including in Saudi patients [28, 29]. Hence, in this study, we
investigated the link between genetic variants in the TNF-α
gene promoter and susceptibility to CRC in a Saudi popula-
tion. Of the three SNPs in the TNF-α gene that were analyzed,
a significant association with CRC was observed only for
TNF-α -238. The other two SNPs, -308 and -857, were not
significantly associated. It was found that in our population
except for the SNP -857 (rs1799724), the other two SNPs, -
308 (rs1800629) and -238 (rs361525), did not follow the
Hardy-Weinberg equilibrium (Table 5). A high rate of consan-
guinity in Saudi Arabia could be a probable cause for this lack
of Hardy-Weinberg equilibrium [30, 31].
A significantly low frequency of the homozygous BA^ al-
lele of TNF-α SNP -238 in the normal control subjects (0.01),
compared to the CRC cases (0.13), implicates this genotype as
a risk factor in the Saudi population. The odds of acquiring
CRC in individuals with AA homozygosity of SNP -238 were
14-fold higher compared to GG homozygotes. The high level
of association between the AA genotype of TNF-α-238 and
CRC existed even after Bonferroni’s correction for multiple
comparisons, suggesting this association was not by chance.
We hypothesize that the -238A allele of the TNF-α genemight
be inducing higher affinity for transcription factor binding,
leading to increased transcription in the tumors. Carriers of
the GG genotype of TNF-α-238 were characterized by low
production of TNF-α by the peripheral blood mononuclear
cells and in the sputum of chronic obstructive pulmonary dis-
ease patients [32, 33]. Additionally, Maxwell and colleagues
demonstrated that the GA genotype at TNF-α -238 was asso-
ciated with a poorer response to infliximab, an anti-TNF agent
in the treatment of rheumatoid arthritis [34].
Recently, Yu et al and Ming et al conducted a comprehen-
sive meta-analysis about TNF-α -238 polymorphism and gas-
tric cancer susceptibility and reported significant associations
in Asian populations [35, 36]. However, another meta-
analysis showed no association with gastric cancer in a differ-
ent patient cohort [37, 38]. A number of studies that investi-
gated the association between TNF-α -238 promoter polymor-
phism and risk of CRC have yielded contradictory results
Table 2 Distribution of TNF-α
SNPs genotype and allele
frequencies in colorectal cancer
cases and control population




OR (95 % CI) χ2 value p value*
rs1800629 GG 67 (0.67) 59 (0.59) Ref
GA 23 (0.23) 23 (0.23) 0.881 (0.448–1.731) 0.14 0.71215
AA 10 (0.10) 18 (0.18) 0.489 (0.209–1.143) 2.79 0.09464
Allele
G 157 (0.785) 141 (0.705) Ref
A 43 (0.215) 59 (0.295) 0.655 (0.416–1.031) 3.37 0.06644
rs361525 GG 86 (0.86) 97 (0.97) Ref
GA 1 (0.01) 2 (0.02) 0.564 (0.050–6.329) 0.22 0.63808
AA 13 (0.13) 1 (0.01) 14.663 (1.879–114.420) 10.94 0.00094
Allele
G 173 (0.865) 196 (0.98) Ref
A 27 (0.135) 4 (0.02) 7.647 (2.624–22.290) 18.50 0.00002
rs1799724 CC 85 (0.85) 85 (0.85) Ref
CT 15 (0.15) 15 (0.15) 1.000 (0.460–2.173) 0.00 1.00000
TT 0 (0.00) 0 (0.00) na na na
Allele
C 185 (0.925) 185 (0.925) Ref
T 15 (0.075) 15 (0.075) 1.000 (0.475–2.105) 0.00 1.00000
CRC colorectal cancer, OR odds ratio, 95 % CI 95 % confidence interval
*p<0.05 was considered significant and are depicted in bold
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[39–41]. A recent meta-analysis on TNF-α-238 polymor-
phism did not find a significant association with CRC
risk [25]. This difference in the predisposition of the
disease related to the SNP could be due to ethnic diver-
sity between populations. Larger studies in the Saudi
population as well as other cohorts are required to
confirm the association of -238 with the risk of CRC
observed in our study.
We found no significant association between TNF-α -308
polymorphism and CRC patients in the overall analysis. Our
results are in agreement with other investigations that did not
find a correlation between TNF-α -308 and sporadic colon
Table 3 Distribution of TNF-α SNPs genotype and allele frequencies in colorectal cancer cases and control population based on age




OR (95 % CI) χ2 value p value*
≤57
rs1800629 GG 31 (0.62) 30 (0.60) Ref
GA 15 (0.30) 14 (0.28) 1.037 (0.428–2.511) 0.01 0.93606
AA 04 (0.08) 06 (0.12) 0.645 (0.165–2.516) 0.40 0.52586
Allele
G 77 (0.77) 74 (0.74) Ref
A 23 (0.23) 26 (0.26) 0.850 (0.446–1.621) 0.24 0.62185
rs361525 GG 43 (0.86) 47 (0.94) Ref
GA 00 (0.00) 02 (0.04) 0.218 (0.010–4.677) 1.79 0.18043
AA 07 (0.14) 01 (0.02) 7.651 (0.904–64.753) 4.64 0.03126
Allele
G 86 (0.86) 96 (0.96) Ref
A 14 (0.14) 04 (0.04) 3.907 (1.239–12.323) 6.11 0.01348
rs1799724 CC 43 (0.86) 43 (0.86) Ref
CT 07 (0.14) 07 (0.14) 1.000 (0.323–3.095) 0.00 1.00000
TT 00 (0.00) 00 (0.00) 1.000 (0.019–51.542) na 1.00000
Allele
C 93 (0.93) 93 (0.93) Ref
T 07 (0.07) 07 (0.07) 1.000 (0.337–2.963) 0.00 1.00000
>57
rs1800629 GG 36 (0.72) 29 (0.58) Ref
GA 08 (0.16) 09 (0.18) 0.716 (0.245–2.089) 0.38 0.53994
AA 06 (0.12) 12 (0.24) 0.403 (0.135–1.204) 2.74 0.09773
Allele
G 80 (0.80) 67 (0.67) Ref
A 20 (0.20) 33 (0.33) 0.508 (0.267–0.966) 4.34 0.03726
rs361525 GG 43 (0.86) 50 (1.00) Ref
GA 01 (0.02) 00 (0.00) 3.483 (0.138–87.708) 1.15 0.28385
AA 06 (0.12) 00 (0.00) 15.092 (0.826–275.623) 6.52 0.01068
Allele
G 87 (0.87) 100 (1.00) Ref
A 13 (0.13) 00 (0.00) 31.011 (1.817–529.290) 13.90 0.00019
rs1799724 CC 42 (0.84) 42 (0.84) Ref
CT 08 (0.16) 08 (0.16) 1.000 (0.343–2.913) 0.00 1.00000
TT 00 (0.00) 00 (0.00) 1.000 (0.019–51.569) na 1.00000
Allele
C 92 (0.92) 92 (0.92) Ref
T 08 (0.08) 08 (0.08) 1.000 (0.360–2.778) 0.00 1.00000
CRC colorectal cancer, OR odds ratio, 95 % CI 95 % confidence interval, na not analyzable
*p<0.05 was considered significant and are depicted in bold
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cancer in a Spanish population [42], a Hungarian population
[43], a Korean population [39], and a Croatian population
[23]. In addition, TNF-α -308 polymorphism was not associ-
ated with colon cancer in any European population in a meta-
analysis conducted by Fan et al, 2011 [44]. Two previous
meta-analyses also reported lack of association of TNF-α -
308 polymorphism with CRC risk [45, 46]. However, a
meta-analysis by Min et al reported TNF-α -308 to be moder-
ately associated with an increased risk of CRC in some
Western populations [25].
Our investigation of the risk of CRC associated with -308
polymorphism found an inverse association with the AA ge-
notype in patients >57 years of age as well as in the unstrati-
fied subjects. An approximately twofold lower risk of CRC
Table 4 Distribution of TNF-α
SNPs genotype and allele
frequencies in colorectal cancer
cases and control population
based on gender




OR (95 % CI) χ2 value p value*
Male
rs1800629 GG 43 (0.67) 36 (0.56) Ref
GA 12 (0.19) 14 (0.22) 0.718 (0.295–1.746) 0.54 0.46359
AA 09 (0.14) 14 (0.22) 0.538 (0.209–1.388) 1.67 0.19644
Allele
G 98 (0.766) 86 (0.672) Ref
A 30 (0.234) 42 (0.328) 0.627 (0.361–1.087) 2.78 0.09529
rs361525 GG 54 (0.844) 62 (0.968) Ref
GA 01 (0.016) 01 (0.016) 1.148 (0.070–18.800) 0.01 0.92279
AA 09 (0.140) 01 (0.016) 10.333 (1.268–84.211) 6.95 0.00837
Allele
G 109 (0.852) 125 (0.977) Ref
A 19 (0.148) 03 (0.023) 7.263 (2.092–25.210) 12.73 0.00036
rs1799724 CC 54 (0.84) 52 (0.81) Ref
CT 10 (0.16) 12 (0.19) 0.802 (0.319–2.017) 0.22 0.63938
TT 00 (0.00) 00 (0.00) 0.963 (0.019–49.443) na 1.00000
Allele
C 118 (0.922) 116 (0.906) Ref
T 10 (0.078) 12 (0.094) 0.819 (0.341–1.970) 0.20 0.65560
Female
rs1800629 GG 24 (0.67) 23 (0.64) Ref
GA 11 (0.30) 09 (0.25) 1.171 (0.410–3.348) 0.09 0.76787
AA 01 (0.03) 04 (0.11) 0.240 (0.025–2.307) 1.75 0.18626
Allele
G 59 (0.819) 55 (0.764) Ref
A 13 (0.181) 17 (0.236) 0.713 (0.317–1.603) 0.67 0.41177
rs361525 GG 32 (0.89) 35 (0.97) Ref
GA 00 (0.00) 01 (0.03) 0.364 (0.014–9.258) 0.90 0.34220
AA 04 (0.11) 00 (0.00) 9.831 (0.509–189.758) 4.12 0.04235
Allele
G 64 (0.889) 71 (0.986) Ref
A 08 (0.111) 01 (0.014) 8.875 (1.080–72.920) 5.81 0.03345
rs1799724 CC 31 (0.86) 33 (0.92) Ref
CT 05 (0.14) 03 (0.08) 1.774 (0.391–8.055) 0.56 0.45325
TT 00 (0.00) 00 (0.00) 1.063 (0.020–55.233) na 1.00000
Allele
C 67 (0.93) 69 Ref
T 05 (0.07) 03 1.716 (0.395–7.467) 0.53 0.71900
CRC colorectal cancer, OR odds ratio and 95% CI 95 % confidence interval, na not analyzable
*p<0.05 was considered significant and are depicted in bold
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for individuals with the AA genotype was noted com-
pared to the GG genotype. However, this association
was not statistically significant. Additionally, in the al-
lelic model, we found that the BA^ allele of TNF-α -
308 presents a significant protective effect against CRC
in individuals >57 years of age. The mechanism behind
this protection cannot be explained and needs further
investigation as the BA^ allele of TNF-α -308 is asso-
ciated with higher expression of the cytokine [47]. The
three TNF-α promoter polymorphisms examined in this
study were also included in an investigation to find an
association of these SNPs with ulcerative colitis-
associated CRC by Garrity-Park et al [26]. The authors
found a strong association only with TNF-α -308 poly-
morphism and ulcerative colitis-associated CRC both at
the genotype and allele levels when compared with ul-
cerative colitis that did not progress to CRC as controls.
The probable cause for the discrepancy between the
results by Garrity-Park et al and our study could be
due to the differences in the patient study population
as they examined a homogenous patient group with ul-
cerative colitis-associated CRCs while our cases mainly
included sporadic CRCs without a history of ulcerative
colitis. Further, we examined the DNA from blood sam-
ples and hence the genotypes represented in our study
subjects were germline while the likelihood of somatic
mutations in the DNA extracted from formalin-fixed
paraffin-embedded biopsies by Garrity-Park and col-
leagues cannot be ruled out [26].
Increased local expression of pro-inflammatory cytokines
such as TNF-α is often detected at sites of inflammation [48].
Studies exploring the genetic association between TNF-α pro-
moter SNPs and altered cytokines expression have been
demonstrated in vivo and in vitro including a link be-
tween -308 SNP and increased TNF-α expression
[49–52]. Higuchi et al reported that the T allele of
TNF-α -857 C/T and the A allele of TNF-α -308 G/A
resulted in higher transcriptional activity and an increase
in TNF-α cytokine production [53]. Thus, it is sug-
gested that the BA^ allele of TNF-α -238 SNP, highly
represented in the CRC cases in our population, may
lead to higher expression of TNF-α in the tumors.
The genotype frequencies of -857 were the same in our
CRC patients compared to control. In our study, the distribu-
tion of the three genotypes in the Saudi population (CC/CT/
TT—cases 85/15/0, controls 85/15/0) were different com-
pared to a Croatian population (CC/CT/TT—cases 130/64/6,
controls 126/67/7) [23]. Moreover, significant correlation be-
tween the TNF-α mRNA expression level in CRC tumor tis-
sue, and prevalence of TNF-α -857 CT and TT genotypes
were reported and may be involved in the progression of colon
cancer [23]. The differences in the distribution of genotype
frequencies of TNF-α -857 could be due to the ethnic diversity
between the two populations.
In conclusion, our study assessed CRC predisposition with
genetic variants in the TNF-α gene in the Saudi population.
While the TNF-α -238 SNP was significantly associated with
CRC risk, SNPs -308 and -857 did not correlate with suscep-
tibility to CRC in our population. Because the population size
in our study was relatively small, these findings need to be
confirmed in larger cohorts. The TNF-α -238 may be a poten-
tial marker for CRC screening in the Saudi population.
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Table 5 Test for deviation from
Hardy-Weinberg equilibrium SNP ID Genotype CRC
n (frequency)
HWE P value Controls
n (frequency)
HWE p value
rs1800629 GG 67 (0.67) 0.001442 59 (0.59) 7.804e-06
GA 23 (0.23) 23 (0.23)
AA 10 (0.10) 18 (0.18)
rs361525 GG 86 (0.86) 1.050e-21 97 (0.97) 9.684e-07
GA 1 (0.01) 2 (0.02)
AA 13 (0.13) 1 (0.01)
rs1799724 CC 85 (0.85) 0.417474 85 (0.85) 0.417474
CT 15 (0.15) 15 (0.15)
TT 0 (0.00) 0 (0.00)
CRC colorectal cancer, HWE Hardy-Weinberg equilibrium
Tumor Biol. (2016) 37:5529–5537 5535
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